Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aptus PharmaBOM:544529 +3.63%18 Median PS Value is ₹0.00 as of Jul. 31, 2026. GuruFocus rates BOM:544529 with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 70 Medical Distribution companies, Aptus Pharma ranks worse than 1428570% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Aptus Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹27.166. Aptus Pharma's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is ₹0.00.
As of today (2026-07-31), Aptus Pharma's share price is ₹278.50. Aptus Pharma's Median PS Value is ₹0.00. Therefore, Aptus Pharma's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Aptus Pharma's Median PS Value or its related term are showing as below:
BOM:544529's Price-to-Median-PS-Value is not ranked *
in the Medical Distribution industry.
Industry Median: 0.84 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Aptus Pharma (BOM:544529) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Aptus Pharma's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
278.50
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aptus Pharma Median PS Value Related Terms
Aptus Pharma Median PS Value Historical Data
* Premium members only.
The historical data trend for Aptus Pharma's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544529 vs MCK, COR, CAH: Median PS Value Comparison
For the Medical Distribution subindustry, Aptus Pharma's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aptus Pharma Price-to-Median-PS-Value vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Aptus Pharma's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Aptus Pharma's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aptus Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹27.166.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aptus Pharma (BOM:544529) has a Median PS Value of ₹0.00 as of Jul. 31, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Aptus Pharma and its competitors. According to the industry distribution chart, Aptus Pharma ranks #999999 out of 70 companies in the Medical Distribution industry.
Is Aptus Pharma's Median PS Value too high?
Aptus Pharma's current Median PS Value is ₹0.00. Based on the distribution chart, Aptus Pharma ranks #999999 out of 70 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Aptus Pharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Aptus Pharma's Median PS Value compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Aptus Pharma ranks #999999 out of 70 companies for Median PS Value. This places Aptus Pharma in the lower half of its industry. The industry median Median PS Value is 0.84. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Distribution company?
The median Median PS Value among Medical Distribution companies is 0.84, based on 70 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Aptus Pharma and its competitors. For the Medical Distribution industry, the median Median PS Value is 0.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aptus Pharma's current Median PS Value is ₹0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptus Pharma stock overvalued right now?
Aptus Pharma (BOM:544529) has a current Median PS Value of ₹0.00. The current Median PS Value is ₹0.00. Aptus Pharma's overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Aptus Pharma (BOM:544529), the current Median PS Value is ₹0.00 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aptus Pharma Ltd is engaged in the business of marketing and distribution of finished pharmaceutical formulations. It operates through a contract manufacturing model. The group provides a diverse range of pharmaceutical products catering to various therapeutic categories, including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, nutritional supplements, pain management, neuro-psychiatric, cardiovascular, anti-diabetic, lipid-lowering, and general wellness products. These are offered across a variety of dosage forms, such as tablets, capsules, softgels, syrups, suspensions, injections, ointments, creams, balms, drops, lotions, vials, powders, gels, and sachets.
18GF Score
Get the complete analysis for BOM:544529
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544529 has been successfully added to your 
